Evidence map›Paper›PMID 30147311›Full record

Observational studyInternational journal of chronic obstructive pulmonary disease2018

Adherence to GOLD guidelines in real-life COPD management in the Puglia region of Italy.

Giuseppe Antonio Palmiotti, Donato Lacedonia, Vito Liotino, Pietro Schino, Francesco Satriano, Pier Luigi Di Napoli, Eugenio Sabato, Vincenzo Mastrosimone, Alfredo Scoditti, Mauro Carone and 4 more

Abstract readMulticenter StudyObservational Study
In one paragraph

Observational study in International journal of chronic obstructive pulmonary disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Reply to GanAmerican journal of respiratory and critical care medicine · 2024
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Are We Missing the Opportunity to Disseminate GOLD Recommendations Through AECOPD Discharge Letters?International journal of chronic obstructive pulmonary disease · 2023
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Does Evaluation and Management of COPD Follow Therapeutic Strategy Recommendations?Chronic obstructive pulmonary diseases (Miami, Fla.) · 2021
    Article
  18. Observational
  19. Compliance of Pharmacotherapy with GOLD Guidelines: A Longitudinal Study in Patients with COPD.International journal of chronic obstructive pulmonary disease · 2020
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Giuseppe Antonio PalmiottiDepartment of Medical and Surgical Sciences, Institute of Respiratory Diseases, University of Foggia, Foggia, Italy, antoniopalmiotti@hotmail.it.
Donato LacedoniaDepartment of Medical and Surgical Sciences, Institute of Respiratory Diseases, University of Foggia, Foggia, Italy, antoniopalmiotti@hotmail.it.
Vito LiotinoDepartment of Cardiac, Thoracic, and Vascular Science, Institute of Respiratory Diseases, School of Medicine, University of Bari, Bari, Italy.
Pietro SchinoPhysiopathology Respiratory Unit, F Miulli General Hospital, Acquaviva delle Fonti, Bari, Italy.
Francesco SatrianoPneumology Clinic, Vito Fazzi Hospital, Lecce, Italy.
Pier Luigi Di NapoliPhysiopathology Respiratory Unit, F Miulli General Hospital, Acquaviva delle Fonti, Bari, Italy.
Eugenio SabatoUOC of Pneumology, "N Melli" Hospital, San Pietro Vernotico, Italy.
Vincenzo MastrosimoneDivision of Pulmonary Disease, Medical Center of Rehabilitation, Foundation Salvatore Maugeri, IRCCS, Marina di Ginosa, Italy.
Alfredo ScodittiDepartment of Respiratory Diseases, San Camillo Clinic, Taranto, Italy.
Mauro CaroneDivision of Pulmonary Disease, Medical Center of Rehabilitation, Foundation Salvatore Maugeri, IRCCS, Cassano delle Murge, Italy.
Elio CostantinoUOC of Pneumology, Hospital "Madonna delle Grazie", Matera, Italy.
Emanuela RestaDepartment of Cardiac, Thoracic, and Vascular Science, Institute of Respiratory Diseases, School of Medicine, University of Bari, Bari, Italy.
Ettore AttoliniRegional Health Agency (ARES), Bari, Italy.
Maria Pia Foschino BarbaroDepartment of Medical and Surgical Sciences, Institute of Respiratory Diseases, University of Foggia, Foggia, Italy, antoniopalmiotti@hotmail.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: COPD is a disease associated with significant economic burden. It was reported that Global initiative for chronic Obstructive Lung Disease (GOLD) guideline-oriented pharmacotherapy improves airflow limitation and reduces health care costs. However, several studies showed a significant dissociation between international recommendations and clinicians' practices. The consequent reduced diagnostic and therapeutic inappropriateness has proved to be associated with an increase in costs and a waste of economic resources in the health sector. The aim of the study was to evaluate COPD management in the Puglia region. The study was performed in collaboration with the pulmonology centers and the Regional Health Agency (AReS Puglia). Methods: An IT platform allowed the pulmonologists to enter data via the Internet. All COPD patients who visited a pneumological outpatient clinic for the first time or for regular follow-ups or were admitted to a pneumological department for an exacerbation were considered eligible for the study. COPD's diagnosis was confirmed by a pulmonologist at the moment of the visit. The project lasted 18 months and involved 17 centers located in the Puglia region. Results: Six hundred ninety-three patients were enrolled, evenly distributed throughout the region. The mean age was 71±9 years, and 85% of them were males. Approximately 23% were current smokers, 63% former smokers and 13.5% never smokers. The mean post-bronchodilator forced expiratory volume in 1 second was 59%±20% predicted. The platform allowed the classification of patients according to the GOLD guidelines (Group A: 20.6%, Group B: 32.3%, Group C: 5.9% and Group D: 39.2%), assessed the presence and severity of exacerbations (20% of the patients had an exacerbation defined as mild [13%], moderate [37%] and severe [49%]) and evaluated the appropriateness of inhalation therapy at the time of the visit. Forty-nine percent of Group A patients were following inappropriate therapy; in Group B, 45.8% were following a therapy in contrast with the guidelines. Among Group C patients, 41.46% resulted in triple combination therapy, whilê14% of Group D patients did not have a therapy or were following an inappropriate therapy. In conclusion, 30% of all patients evaluated had been following an inadequate therapy. Subsequently, an online survey was developed to inquire about the reasons for the results obtained. In particular, we investigated the reasons why 30% of our population did not follow the therapy suggested by the GOLD guidelines: 1) why was there an excessive use of inhaled corticosteroids, 2) why a significantly high percentage was inappropriately treated with triple therapy and 3) why a consistent percentage (11%) of Group D patients were not treated at all. Conclusion: The data provides an overview on the management of COPD in the region of Puglia (Italy) and represents a resource in order to improve appropriateness and reduce the waste of health resources.

Indexed as

Guideline AdherenceAdultAgedBronchodilator AgentsCross-Sectional StudiesFemaleForced Expiratory VolumeHumansItalyMaleMiddle AgedPractice Patterns, Physicians'Pulmonary Disease, Chronic ObstructiveSeverity of Illness IndexTreatment OutcomeBronchodilator AgentsappropriatenessCOPDhealth care spendingonline surveyweb platform

Identifiers

PMID30147311
PMCPMC6101739

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.